Javier Soto Alsar

Javier Soto Alsar


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JAJavier Soto Alsar
Javier Soto Alsar
CPCoral Polo
Coral Polo
ECEnrique Luis Álvarez Castillo
Enrique Luis Álvarez Castillo
MMMaría del Monte-Millan
María del Monte-Millan
NANatalia Gutiérrez Alonso
Natalia Gutiérrez Alonso
PAPilar García Alfonso
Pilar García Alfonso
Background/Objectives: BRAF-mutated (BRAFmut) colorectal cancer (CRC) is associated with a poor prognosis. In the metastatic setting, the role of metastasectomy in this subgroup remains controversial. However, treatment-induced molecular changes may help identify patients who are more likely to benefit from surgical resection of metastatic disease. Methods: A case-control study was conducted involving 14 patients with metastatic CRC, including 7 with BRAF-mutated tumors (case group) and 7 with tumors that were wild type for both RAS or BRAF (control group). Whole-exome sequencing (WES) was performed on FFPE tissue samples obtained before and after systemic therapy. All patients subsequently underwent surgical resection of metastatic lesions. Patients were matched according to primary tumor location (left- vs right-sided) and the site of metastasectomy (liver or peritoneal metastases). Results: Most patients underwent surgical resection of liver metastases (57%), followed by resection of peritoneal metastases (43%). All patients received fluoropyrimidine-based chemotherapy (capecitabine or 5-fluorouracil) in combination with oxaliplatin, and 36% also received irinotecan In addition, 64% received anti-angiogenic therapy (bevacizumab or aflibercept) and 14% received panitumumab. Distinct patterns of post-treatment mutational gain or loss were observed between the Case and Control groups. Furthermore, the profiles of altered genes differed according to metastatic site, primary tumor sidedness, and treatment regimen. No significant differences in overall survival or event-free survival were observed between the two groups. Conclusions: The mutational landscape of mCRC is dynamic rather than static, evolving in response to systemic therapy, the metastatic microenvironment, and the underlying molecular background. These findings support the potential clinical value of incorporating longitudinal genomic monitoring into therapeutic decision-making to identify treatment-induced evolutionary changes and optimize systemic treatment strategies.